Yim S - Search Results

1

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis.

Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, Kim C, Sun W, Zhou L, Grosser S, Yim S, Ricci MS. Herndon TM, et al. Among authors: yim s. PLoS One. 2023 Oct 3;18(10):e0292231. doi: 10.1371/journal.pone.0292231. eCollection 2023. PLoS One. 2023. PMID: 37788264 Free PMC article.

2

Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.

Shubow S, Sun Q, Nguyen Phan AL, Hammell DC, Kane M, Lyman GH, Gibofsky A, Lichtenstein GR, Bloomgarden Z, Cross RK, Yim S, Polli JE, Wang YM. Shubow S, et al. Among authors: yim s. Clin Pharmacol Ther. 2023 Jan;113(1):37-49. doi: 10.1002/cpt.2765. Epub 2022 Nov 4. Clin Pharmacol Ther. 2023. PMID: 36251545 Free PMC article. Review.

3

The Science of Biosimilars-Updating Interchangeability.

Cavazzoni P, Yim S. Cavazzoni P, et al. Among authors: yim s. JAMA. 2024 Oct 15;332(15):1235-1236. doi: 10.1001/jama.2024.15225. JAMA. 2024. PMID: 39292484

4

Impact of Sex on Clinical Response in Rheumatoid Arthritis Patients Treated With Biologics at Approved Dosing Regimens.

Fang L, Sonvg X, Ji P, Wang Y, Maynard J, Yim S, Sahajwalla C, Xu M, Kim MJ, Zhao L. Fang L, et al. Among authors: yim s. J Clin Pharmacol. 2020 Dec;60 Suppl 2:S103-S109. doi: 10.1002/jcph.1776. J Clin Pharmacol. 2020. PMID: 33274512

5

Dosing regimen determination for juvenile idiopathic arthritis: a review of studies during drug development.

Ji P, Chowdhury BA, Yim S, Sahajwalla CG. Ji P, et al. Among authors: yim s. J Pharm Sci. 2012 Aug;101(8):2621-34. doi: 10.1002/jps.23184. Epub 2012 May 31. J Pharm Sci. 2012. PMID: 22653876 Review.

6

Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation.

Ma L, Zhao L, Xu Y, Yim S, Doddapaneni S, Sahajwalla CG, Wang Y, Ji P. Ma L, et al. Among authors: yim s. J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):537-43. doi: 10.1007/s10928-014-9385-x. Epub 2014 Oct 5. J Pharmacokinet Pharmacodyn. 2014. PMID: 25283268

7

Exposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 1: Binary Model).

Li L, Zhang Y, Ma L, Ji P, Yim S, Chowdhury B, Doddapaneni S, Liu J, Wang Y, Sahajwalla C. Li L, et al. Among authors: yim s. J Clin Pharmacol. 2017 Sep;57(9):1097-1106. doi: 10.1002/jcph.891. J Clin Pharmacol. 2017. PMID: 28817199 Clinical Trial.

8

Exposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 2: Continuous Model).

Li L, Zhang Y, Ma L, Ji P, Yim S, Chowdhury BA, Doddapaneni S, Liu J, Wang Y, Sahajwalla C. Li L, et al. Among authors: yim s. J Clin Pharmacol. 2017 Sep;57(9):1107-1125. doi: 10.1002/jcph.967. J Clin Pharmacol. 2017. PMID: 28817201 Clinical Trial.

9

Regulatory aspects of new medicines targeted at treatment of autoimmune diseases.

Hull KM, Yim S. Hull KM, et al. Among authors: yim s. Clin Pharmacol Ther. 2012 Apr;91(4):739-42. doi: 10.1038/clpt.2012.5. Epub 2012 Mar 7. Clin Pharmacol Ther. 2012. PMID: 22398965 Review.

10

Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: Identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI.

Joseph S, George NI, Green-Knox B, Treadwell EL, Word B, Yim S, Lyn-Cook B. Joseph S, et al. Among authors: yim s. J Autoimmun. 2019 Jan;96:147-157. doi: 10.1016/j.jaut.2018.09.007. Epub 2018 Oct 7. J Autoimmun. 2019. PMID: 30301579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,093 results

Search Page

Filters